| Toward quantitative neurosurgical guidance with high-resolution microscopy of 5-aminolevulinic acid-induced protoporphyrin IX L Wei, Y Fujita, N Sanai, JTC Liu Frontiers in Oncology 9, 592, 2019 | 24 | 2019 |
| Handheld line-scanned dual-axis confocal microscope with pistoned MEMS actuation for flat-field fluorescence imaging L Wei, C Yin, Y Fujita, N Sanai, JTC Liu Optics letters 44 (3), 671-674, 2019 | 19 | 2019 |
| New approaches to glioblastoma M Khasraw, Y Fujita, C Lee-Chang, IV Balyasnikova, H Najem, ... Annual review of medicine 73, 279-292, 2022 | 18 | 2022 |
| IDH1 p. R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas Y Fujita, L Nunez-Rubiano, A Dono, A Bellman, M Shah, JC Rodriguez, ... Journal of neuro-oncology 159 (2), 261-270, 2022 | 10 | 2022 |
| Video-Mosaicked Handheld Dual-Axis Confocal Microscopy of Gliomas: An ex vivo Feasibility Study in Humans Y Fujita, L Wei, PJ Cimino, JTC Liu, N Sanai Frontiers in Oncology 10, 1674, 2020 | 6 | 2020 |
| MNGI-01. A phase 0 trial of ribociclib in aggressive meningioma patients incorporating a tumor pharmacodynamic-and pharmacokinetic-guided expansion cohort AC Tien, J Li, X Bao, A DeRogatis, Y Fujita, C Pennington-Krygier, S Kim, ... Neuro-Oncology 21 (Supplement_6), vi139-vi139, 2019 | 4 | 2019 |
| A phase 0/II clinical trial of a CDK4/6 inhibitor in aggressive meningioma patients N Sanai, AC Tien, J Li, X Bao, A DeRogatis, Y Fujita, ... Annals of Oncology 30, v144, 2019 | 2 | 2019 |
| The genomic alterations in glioblastoma influence the levels of CSF metabolites DH Wang, Y Fujita, A Dono, AG Rodriguez Armendariz, M Shah, N Putluri, ... Acta Neuropathologica Communications 12 (1), 13, 2024 | 1 | 2024 |
| SINGLE CELL TRANSCRIPTOMICS, PHARMACOKINETICS, AND PHARMACODYNAMICS OF COMBINED CDK4/6 AND MTOR INHIBITION IN A PHASE 0 TRIAL OF RECURRENT HIGH-GRADE GLIOMA K Johnson, AC Tien, J Jiang, J McNamara, YW Chang, C Montgomery, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
| Single nuclei RNAseq analysis of recurrent high-grade glioma tumors from patients in the phase 0/1 ‘trigger’trial of ribociclib plus everolimus N Sanai, AC Tien, K Johnson, J Jiang, YW Chang, C Montgomery, ... Cancer Research 83 (7_Supplement), 3404-3404, 2023 | | 2023 |
| CTNI-54. A PHASE 0/1 ‘TRIGGER’TRIAL OF RIBOCICLIB PLUS EVEROLIMUS IN RECURRENT HIGH-GRADE GLIOMA N Sanai, AC Tien, J Jiang, YW Chang, C Montgomery, A DeSantis, ... Neuro-Oncology 24 (Suppl 7), vii84, 2022 | | 2022 |
| CTNI-22. A PHASE 0/1 ‘TRIGGER’TRIAL OF RIBOCICLIB PLUS EVEROLIMUS IN RECURRENT HIGH-GRADE GLIOMA N Sanai, AC Tien, J Jiang, YW Chang, C Pennington-Krygier, A DeSantis, ... Neuro-Oncology 23 (Suppl 6), vi64, 2021 | | 2021 |
| Predicting the Future Relapse of Patients With Alcohol Use Disorder Using Tasks of Working Memory and Probability-Based Decision Making J Sasaki, T Matsubara, C Chen, Y Fujii, M HIrotsu, M Nakamuta, Y Fujita, ... Biological Psychiatry 87 (9), S323-S324, 2020 | | 2020 |
| SURG-04. INTRAOPERATIVE HAND-HELD LINE-SCANNED DUAL-AXIS CONFOCAL MICROSCOPY FOR VISUALIZING LOW-GRADE GLIOMAS Y Fujita, L Wei, JTC Liu, N Sanai Neuro-Oncology 21 (Suppl 6), vi240, 2019 | | 2019 |
| 10 Emerging Chemotherapy and Targeted Therapy for Aggressive Meningiomas Y Fujita, BK Hendricks, N Sanai Controversies in Skull Base Surgery, 58, 2019 | | 2019 |
| OS8. 1 A phase 0/2 clinical trial of a CDK4/6 inhibitor in aggressive meningioma patients A Tien, J Li, X Bao, A DeRogatis, Y Fujita, C Pennington-Krygier, S Kim, ... Neuro-Oncology 21 (Suppl 3), iii15, 2019 | | 2019 |
